4 Analysts Have This To Say About Cross Country Healthcare
Portfolio Pulse from Benzinga Insights
Cross Country Healthcare (NASDAQ:CCRN) has received mixed analyst ratings over the past quarter, with recent evaluations adjusting price targets and ratings due to changing market dynamics and company performance. The average 12-month price target is now $21.25, a 15.0% decrease from the previous $25.00. Analysts from Truist Securities, Benchmark, UBS, and Barrington Research have adjusted their ratings and price targets, reflecting concerns over the company's revenue decline of -30.47% as of September 30, 2023, and operational challenges. Despite this, CCRN's net margin and ROE outperform industry benchmarks, indicating efficient cost management and financial health.
February 22, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cross Country Healthcare's mixed analyst ratings and adjusted price targets reflect concerns over its significant revenue decline and operational challenges, despite strong net margin and ROE.
The significant revenue decline of -30.47% as of September 30, 2023, is a major concern for investors, indicating operational challenges. However, the company's strong net margin and ROE suggest efficient cost management and financial health. The mixed analyst ratings and adjusted price targets reflect the market's reaction to these factors, likely leading to short-term negative impact on CCRN's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100